| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gahan Pandina, Stuart Kushner, Keith Karcher, Magali Haa. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child and adolescent psychiatry and mental health. vol 6. issue 1. 2012-11-07. PMID:22676070. |
the objective of this study was to evaluate the efficacy and safety of maintenance risperidone treatment in adolescents with schizophrenia. |
2012-11-07 |
2023-08-12 |
Not clear |
| Stefan Smesny, Kerstin Langbein, Reinhardt Rzanny, Alexander Gussew, Hartmut P Burmeister, Juergen R Reichenbach, Heinrich Saue. Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients. Schizophrenia research. vol 138. issue 2-3. 2012-10-24. PMID:22516552. |
antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31p-2d-csi study of haloperidol and risperidone in acutely ill chronic schizophrenia patients. |
2012-10-24 |
2023-08-12 |
Not clear |
| James I Wasserman, Rebecca J Barry, Lisa Bradford, Nicholas J Delva, Richard J Beninge. Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. Psychopharmacology. vol 222. issue 1. 2012-10-22. PMID:22237855. |
probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. |
2012-10-22 |
2023-08-12 |
Not clear |
| Shugui Gao, Zhenyu Hu, Jia Cheng, Wenhua Zhou, Yongming Xu, Shuguang Xie, Shiyan Liu, Zaizhong Li, Junming Guo, Jianyi Dong, Minfang Huan. Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. Clinical biochemistry. vol 45. issue 10-11. 2012-10-22. PMID:22560999. |
impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. |
2012-10-22 |
2023-08-12 |
Not clear |
| Shugui Gao, Zhenyu Hu, Jia Cheng, Wenhua Zhou, Yongming Xu, Shuguang Xie, Shiyan Liu, Zaizhong Li, Junming Guo, Jianyi Dong, Minfang Huan. Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. Clinical biochemistry. vol 45. issue 10-11. 2012-10-22. PMID:22560999. |
the main aim was to study the effects of comt polymorphisms on response of risperidone treatment for schizophrenia and investigate the correlation between memory function of schizophrenia patients and comt polymorphisms. |
2012-10-22 |
2023-08-12 |
Not clear |
| Basak Togar, Hasan Turkez, Abdulgani Tatar, Ismet Kirkpinar, Ahmet Hacimuftuoglu, Fatime Geyikoglu, M Sait Keles, Ebubekir Dirica. The genotoxic potentials of some atypical antipsychotic drugs on human lymphocytes. Toxicology and industrial health. vol 28. issue 4. 2012-10-17. PMID:21937534. |
olanzapine (olz), risperidone (rpd) and quetiapine (qtp) are atypical antipsychotic drugs and are commonly used for the treatments of schizophrenia and bipolar disorders. |
2012-10-17 |
2023-08-12 |
human |
| Hui-Chih Chang, Chao-Hsiun Tang, Sheng-Tzu Huang, Paul McCrone, Kuan-Pin S. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. Journal of psychiatric research. vol 46. issue 6. 2012-10-17. PMID:22440883. |
a cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in taiwan. |
2012-10-17 |
2023-08-12 |
Not clear |
| Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Kenji Hayashi, Atsuko Ikenouchi-Sugita, Wakako Umene-Nakano, Jun Nakamur. The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. Journal of psychiatric research. vol 46. issue 6. 2012-10-17. PMID:22464338. |
we investigated the effects of the atypical antipsychotics risperidone, olanzapine, and aripiprazole on the cognitive functions of japanese patients with schizophrenia with respect to dosage amounts and dosing schedules. |
2012-10-17 |
2023-08-12 |
Not clear |
| Ran Huo, Kefu Tang, Zhiyun Wei, Lu Shen, Yuyu Xiong, Xi Wu, Jiamin Niu, Xia Han, Zhengan Tian, Lun Yang, Guoyin Feng, Lin He, Shengying Qi. Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. PloS one. vol 7. issue 5. 2012-10-16. PMID:22606226. |
genetic polymorphisms in cyp2e1: association with schizophrenia susceptibility and risperidone response in the chinese han population. |
2012-10-16 |
2023-08-12 |
Not clear |
| Ran Huo, Kefu Tang, Zhiyun Wei, Lu Shen, Yuyu Xiong, Xi Wu, Jiamin Niu, Xia Han, Zhengan Tian, Lun Yang, Guoyin Feng, Lin He, Shengying Qi. Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. PloS one. vol 7. issue 5. 2012-10-16. PMID:22606226. |
we investigated the possible association of cyp2e1 polymorphisms with susceptibility to schizophrenia in the chinese han population as well as the relationship with response to risperidone in schizophrenia patients. |
2012-10-16 |
2023-08-12 |
Not clear |
| Mingzhu Huang, Jianzhong Shen-Tu, Xingjiang Hu, Junchun Chen, Jian Liu, Lihua W. Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers. Clinical therapeutics. vol 34. issue 6. 2012-10-11. PMID:22595151. |
risperidone (ris), an atypical antipsychotic drug, is used for the treatment of psychoses associated with schizophrenia and other psychiatric disorders in adult and pediatric populations. |
2012-10-11 |
2023-08-12 |
human |
| Ramy A Mahmoud, Luella M Engelhart, Carmela C Janagap, Gerry Oster, Dan Ollendor. Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care. Clinical drug investigation. vol 24. issue 5. 2012-10-02. PMID:17503889. |
risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder : symptoms, quality of life and resource use under customary clinical care. |
2012-10-02 |
2023-08-12 |
Not clear |
| Ramy A Mahmoud, Luella M Engelhart, Carmela C Janagap, Gerry Oster, Dan Ollendor. Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care. Clinical drug investigation. vol 24. issue 5. 2012-10-02. PMID:17503889. |
to prospectively compare risperidone with conventional antipsychotic agents among schizophrenia patients treated under usual practice conditions. |
2012-10-02 |
2023-08-12 |
Not clear |
| Kazuyuki Fujita, Toshihiko Fukuchi, Shoji Yuasa, Eriko Inada, Yoko Tarao, Kousuke Kanemot. Switch from risperidone to perospirone in patients with chronic schizophrenia. Clinical drug investigation. vol 24. issue 5. 2012-10-02. PMID:17503891. |
switch from risperidone to perospirone in patients with chronic schizophrenia. |
2012-10-02 |
2023-08-12 |
Not clear |
| J Bobes, M Gutiérrez, J Gibert, M Gonzalez, L Herraiz, A Fernánde. Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. European psychiatry : the journal of the Association of European Psychiatrists. vol 13. issue 3. 2012-10-02. PMID:19698620. |
quality of life in schizophrenia: long-term follow-up in 362 chronic spanish schizophrenic outpatients undergoing risperidone maintenance treatment. |
2012-10-02 |
2023-08-12 |
Not clear |
| P Bech, J C Peuskens, S R Marder, G Chouinard, O J Høyberg, M O Huttunen, O Blin, A Clau. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. European psychiatry : the journal of the Association of European Psychiatrists. vol 13. issue 6. 2012-10-02. PMID:19698646. |
meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. |
2012-10-02 |
2023-08-12 |
Not clear |
| P Bech, J C Peuskens, S R Marder, G Chouinard, O J Høyberg, M O Huttunen, O Blin, A Clau. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. European psychiatry : the journal of the Association of European Psychiatrists. vol 13. issue 6. 2012-10-02. PMID:19698646. |
data from six randomised, controlled, comparative studies of risperidone and conventional neuroleptics (haloperidol, zuclopenthixol and perphenazine) in the treatment of 911 patients with chronic schizophrenia were analysed to estimate the benefits and risks of treatment. |
2012-10-02 |
2023-08-12 |
Not clear |
| Haya Ascher-Svanum, William S Montgomery, David P McDonnell, Kristina A Coleman, Peter D Feldma. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. International journal of general medicine. vol 5. 2012-10-02. PMID:22615534. |
treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. |
2012-10-02 |
2023-08-12 |
Not clear |
| Haya Ascher-Svanum, William S Montgomery, David P McDonnell, Kristina A Coleman, Peter D Feldma. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. International journal of general medicine. vol 5. 2012-10-02. PMID:22615534. |
due to the absence of head-to-head studies comparing olanzapine long-acting injection and risperidone long-acting injection, this study was intended to make exploratory, indirect, cross-study comparisons between the long-acting formulations of these two atypical antipsychotics in their effectiveness in treating patients with schizophrenia. |
2012-10-02 |
2023-08-12 |
Not clear |
| Hyun-Ghang Jeong, Moon-Soo Lee, Hwa-Young Lee, Young-Hoon Ko, Changsu Han, Sook-Haeng Jo. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International clinical psychopharmacology. vol 27. issue 4. 2012-09-27. PMID:22407277. |
in this prospective, open-label study, the participants were 10 male schizophrenia patients treated with atypical antipsychotics, risperidone, amisulpride, and olanzapine. |
2012-09-27 |
2023-08-12 |
human |